Revance Therapeutics Stock Price - RVNC

0.00 (0.00%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
Level 1 Starter
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Revance Therapeutics Inc RVNC NASDAQ Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
0.23 0.83% 27.81 27.25 27.97 27.57 27.58 00:00:05
Bid Price Ask Price Spread Spread % News
24.33 36.99 12.66 34.23% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
11,178 1,401,300 $ 27.68 $ 38,784,179 1,053,599 9.88 - 27.97
Last Trade Time Type Quantity Stock Price Currency
16:59:04 formt 7,848 $ 27.81 USD

Revance Therapeutics Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 1.49B 53.40M $ -142.57M -3.94 - 52.56M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Revance Therapeutics News

Loading Messages....

Latest RVNC Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical RVNC Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week24.7427.9724.3526.41763,8023.0712.41%
1 Month22.4027.9721.1324.471,002,7205.4124.15%
3 Months17.8527.9715.3720.51894,9079.9655.8%
6 Months11.2527.979.8818.35607,42916.56147.2%
1 Year18.0027.979.8816.42502,0269.8154.5%
3 Years21.1537.459.8821.99366,9006.6631.49%
5 Years15.7142.459.8822.58316,27412.1077.02%

Revance Therapeutics Description

Revance Therapeutics Inc is a clinical-stage biotechnology company. It is focused on the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic indications. The company's proprietary peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical. The company is pursuing clinical development for RT002 injectable in a broad spectrum of aesthetic and therapeutic indications. It holds rights for all indications of RT002 injectable and RT001 topical, and the pharmaceutical uses of its proprietary peptide technology.

Your Recent History
Revance Th..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.